Wyeth is now a wholly owned subsidiary of Pfizer
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Wyeth is now a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).
Wyeth is now a wholly owned subsidiary of Pfizer: 167 sponsored US clinical trials, none currently recruiting.
Wyeth is now a wholly owned subsidiary of Pfizer sponsors 167 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 139 completed. 53 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 5 trials.
Top-decile sponsor footprint
Wyeth is now a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
139 of 167 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
167 total, page 4 of 4
Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
NCT00092976
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
NCT00086346
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
NCT00037557
Study Evaluating rhIL-11 in Active Crohn's Disease
NCT00040521
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
NCT00161668
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
NCT00037570
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
NCT00044733
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
NCT00002266
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
NCT00063219
A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients
NCT00002013
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
NCT00037531
Study Evaluating TMI-005 in Active Rheumatoid Arthritis
NCT00095342
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
NCT00044759
Study Evaluating rFIX; BeneFIX® in Hemophilia B
NCT00093171
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
NCT00424892
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
NCT00277836
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
NCT00088647
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 74 |
| Phase 2 | 28 |
| Phase 3 | 43 |
| Phase 4 | 10 |
Therapeutic Areas
How the Wyeth is now a wholly owned subsidiary of Pfizer early-phase archive is shaped
167 indexed studies, none listed as recruiting (0% open); 139 completed (83%).
Phase mix: 53 late (III/IV) vs 102 early (I/II) (early-phase heavy).
Top condition: Healthy (5 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Wyeth is now a wholly owned subsidiary of Pfizer: archived-pipeline peers nationwide
Peers matched on 167 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 167 archived trials
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Wyeth is now a wholly owned subsidiary of Pfizer page
167 registered trials is a research-attention snapshot, not an endorsement of Wyeth is now a wholly owned subsidiary of Pfizer or any single study.
- None of Wyeth is now a wholly owned subsidiary of Pfizer's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Wyeth is now a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wyeth is now a wholly owned subsidiary of Pfizer pipeline card: 167 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.